Effects on 24-hour intragastric pH: A comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously

American Journal of Gastroenterology

Volumn 96, Issue 7, 2001, Pages 2058-2065

  Freston, James ^a   Chiu, Yi Lin ^b   Pan, Wei Jian ^b   Lukasik, Nancy ^c   Täubel, Jörg ^d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c TAP Pharmaceuticals   (United States)

^d Stamford Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PANTOPRAZOLE;

ADULT; APPLE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; NASOGASTRIC TUBE; NORMAL HUMAN; PATIENT MONITORING; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; KINETICS; MALE; OMEPRAZOLE; PROTON PUMPS; RANDOM ALLOCATION; ROSALES; STOMACH; SULFOXIDES;

EID: 0034932785     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02502-3     Document Type: Article

References (22)

1. Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs
2. Is there an optimal degree of acid suppression for healing of duodenal ulcer? A model of the relationship between ulcer healing and acid suppression
3. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
4. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
5. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers
6. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion
7. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring
8. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion, and serum gastrin in healthy volunteers
9. Influence of lansoprazole 15 mg and omeprazole 20 mg and 40 mg on meal-stimulated gastric acid secretion
10. Comparison of the effects of lansoprazole and omeprazole on 24-hour gastric pH in normal male volunteers
11. Age-related differences in the pharmacokinetics, and pharmacodynamics of lansoprazole
12. Pharmacokinetics and metabolism of omeprazole in man
13. Lansoprazole. An alternative method of administration of a capsule dosage formulation
14. Lanosprazole. Administration of the contents of a capsule dosage formulation through a nasogastric tube
15. The pharmacodynamics of lansoprazole administered via gastostomy as intact, non-encapsulated granules
16. Alternative methods of proton pump inhibitor administration
17. Lanosoprazole effectively suppresses intragastric acidity when administered via gastrostomy as intact granules in orange juice
18. Simplified lansoprazole suspension (SLS): A proton pump inhibitor (PPI) in a liquid formulation that works
19. Inhibition of pentagastrin-indued gastric acid secretion by intravenous pantoprazole: A dose-response study
20. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole
21. Twenty-four hour monitoring of intragastric acidity: Comparison between lansoprazole 30 mg and pantoprazole 40 mg
22. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease